My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 220

    1.

    The effect of ruboxistaurin on nephropathy in type 2 diabetes.

    Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW.

    Diabetes Care. 2005 Nov;28(11):2686-90.PMID: 16249540 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

    Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group.

    Clin Ther. 2005 Aug;27(8):1164-80.PMID: 16199243 [PubMed - indexed for MEDLINE]Related articles

    3.

    Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

    Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

    4.

    A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.

    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI.

    Diabetes Care. 2007 Apr;30(4):896-902.PMID: 17392551 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.

    Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW; PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups.

    Clin J Am Soc Nephrol. 2007 Jul;2(4):631-6. Epub 2007 May 30.PMID: 17699475 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

    PKC-DRS2 Group, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.

    Ophthalmology. 2006 Dec;113(12):2221-30. Epub 2006 Sep 20.PMID: 16989901 [PubMed - indexed for MEDLINE]Related articles

    7.

    Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

    Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group.

    Am J Nephrol. 2004 Jan-Feb;24(1):32-40. Epub 2003 Dec 17.PMID: 14685005 [PubMed - indexed for MEDLINE]Related articles

    8.

    Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.

    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.

    J Hypertens. 2006 Nov;24(11):2285-92.PMID: 17053552 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.

    Gilbert RE, Kim SA, Tuttle KR, Bakris GL, Toto RD, McGill JB, Haney DJ, Kelly DJ, Anderson PW.

    Diabetes Care. 2007 Apr;30(4):995-6. Epub 2007 Jan 17. No abstract available. PMID: 17229944 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

    Diabetes Care. 2005 Nov;28(11):2728-32.PMID: 16249547 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    12.

    Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group.

    N Engl J Med. 2004 Nov 4;351(19):1952-61. Epub 2004 Oct 31. Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731. PMID: 15516696 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

    Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS.

    Control Clin Trials. 1999 Oct;20(5):493-510.PMID: 10503809 [PubMed - indexed for MEDLINE]Related articles

    14.

    Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

    Rossing K, Christensen PK, Jensen BR, Parving HH.

    Diabetes Care. 2002 Jan;25(1):95-100.PMID: 11772908 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.

    Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C; Melbourne Diabetic Nephropathy Study Group.

    Diabet Med. 2004 Nov;21(11):1192-9.PMID: 15498085 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.

    Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.

    Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3855-8.PMID: 16186374 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.

    BENEDICT Group.

    Control Clin Trials. 2003 Aug;24(4):442-61.PMID: 12865039 [PubMed - indexed for MEDLINE]Related articles

    18.

    Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.

    Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE.

    Invest Ophthalmol Vis Sci. 2006 Jan;47(1):86-92.PMID: 16384948 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

    Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S.

    J Int Med Res. 2005 Nov-Dec;33(6):677-86.PMID: 16372586 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.

    PKC-DMES Study Group.

    Arch Ophthalmol. 2007 Mar;125(3):318-24.PMID: 17353401 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity